a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical ...

Fintel reports that on November 13, 2024, JMP Securities downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) ...

Despite a revenue drop, Syros Pharmaceuticals Inc (SYRS) advances its promising pipeline with a pivotal trial and financial stability.

Exscientia (NASDAQ:EXAI – Get Free Report) and Quince Therapeutics (NASDAQ:QNCX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two ...

Operator: Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At ...

Protein folding is the process by which proteins achieve their mature functional (native) tertiary structure, and often begins co-translationally. Protein folding requires chaperones and often ...

Exscientia’s current clinical-stage pipeline consists of CDK7 inhibitor GTAEXS-617, which is co-owned with GT Apeiron, Evotec-partnered A2A receptor antagonist EXS-21546, and BMS-partnered PKC ...

The firm also paused development of the acute promyelocytic leukemia agent SY-2101 and was seeking to out-license the CDK7 inhibitor SY-5609.

Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China ...

Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Note that this call is being ...